12 May 2026 - BridgeBio Pharma today announced the submission of its new drug application to the FDA for encaleret as a potential targeted treatment for autosomal dominant hypocalcaemia type 1.

CALIBRATE, the Phase 3 clinical trial of encaleret in autosomal dominant hypocalcaemia type 1., successfully achieved all pre-specified primary and key secondary efficacy endpoints, supporting encaleret’s potential as a disease-modifying therapy by targeting the underlying genetic cause of autosomal dominant hypocalcaemia type 1.

Read Bridge Bio Pharma press release